Atb Cap Markets Has Negative Outlook for OGI FY2028 Earnings

Key Points

• Analysts at Atb Cap Markets have revised down their FY2028 earnings per share estimate for Organigram Global Inc. from $0.11 to $0.10, while the consensus expectation remains at ($0.19) per share.
• Organigram's recent quarterly earnings report showed a loss of ($0.03) EPS, missing analysts' expectations; the company also reported revenues of $50.49 million, which fell short of the projected $68.04 million.
• The stock price of Organigram has seen fluctuations, recently trading at $1.52, with a market capitalization of $203.06 million and shares owned by institutional investors accounting for 34.63% of total shares.

Organigram Global Inc. (NASDAQ:OGI - Free Report) - Stock analysts at Atb Cap Markets reduced their FY2028 EPS estimates for Organigram Global in a research note issued to investors on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now anticipates that the company will post earnings of $0.10 per share for the year, down from their prior estimate of $0.11. The consensus estimate for Organigram Global's current full-year earnings is ($0.19) per share.

Organigram Global (NASDAQ:OGI - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). Organigram Global had a negative return on equity of 8.19% and a net margin of 2.86%.The company had revenue of $50.49 million for the quarter, compared to the consensus estimate of $68.04 million.

Separately, Wall Street Zen lowered shares of Organigram Global from a "hold" rating to a "sell" rating in a report on Saturday.

Organigram Global Stock Down 1.3%

Organigram Global stock traded down $0.02 on Friday, hitting $1.50. The company's stock had a trading volume of 593,757 shares, compared to its average volume of 728,505. The firm has a market cap of $201.08 million, a P/E ratio of 30.01 and a beta of 1.45. The company has a fifty day moving average price of $1.43 and a 200-day moving average price of $1.27. Organigram Global has a one year low of $0.85 and a one year high of $2.0550.

Institutional Investors Weigh In On Organigram Global

Large investors have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new stake in shares of Organigram Global in the 4th quarter worth about $26,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Organigram Global in the 1st quarter worth about $30,000. Oxford Asset Management LLP bought a new stake in shares of Organigram Global in the 4th quarter worth about $50,000. Cidel Asset Management Inc. grew its holdings in shares of Organigram Global by 112.3% in the 2nd quarter. Cidel Asset Management Inc. now owns 37,103 shares of the company's stock worth $50,000 after purchasing an additional 19,627 shares during the last quarter. Finally, Clear Harbor Asset Management LLC bought a new stake in shares of Organigram Global in the 2nd quarter worth about $54,000. Institutional investors own 34.63% of the company's stock.

Organigram Global Company Profile

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.